Retatrutide Benefits Beyond Weight Loss

Retatrutide may have benefits beyond weight loss because obesity can affect many areas of health, including blood sugar, blood pressure, cholesterol, joints, breathing during sleep and liver fat.

Clinical trials suggest retatrutide may help improve several obesity-related health markers. These include A1C, waist circumference, triglycerides, non-HDL cholesterol, systolic blood pressure, liver fat, obstructive sleep apnoea severity and knee osteoarthritis pain.

These benefits are still being studied. Retatrutide remains an investigational medicine and is not currently approved for routine medical use in the UK.

Further reading: Buying retatrutide in the UK

One of the most important potential benefits of retatrutide beyond weight loss is improved blood sugar control.

In clinical trials involving people with type 2 diabetes, retatrutide reduced A1C, which is a blood test that reflects average blood sugar levels over time. Some participants also reached lower A1C thresholds during treatment.

This may be important because obesity and type 2 diabetes often occur together. A treatment that reduces weight and improves blood sugar may have wider metabolic benefits.

However, retatrutide is not currently approved as a diabetes treatment in the UK.

Retatrutide may reduce waist circumference.

Waist circumference is a useful marker because excess abdominal fat is linked with higher cardiometabolic risk. A reduction in waist size may reflect a reduction in central fat, which is often associated with improvements in blood pressure, cholesterol and blood sugar control.

This does not mean retatrutide specifically targets belly fat. Fat loss usually happens across the body over time.

Retatrutide may improve some cholesterol markers.

Clinical trial data has shown reductions in non-HDL cholesterol. Non-HDL cholesterol includes several types of cholesterol linked with cardiovascular risk.

This may be relevant because people living with obesity may also have raised cholesterol or other cardiometabolic risk factors. More research is needed to understand whether these changes reduce long-term cardiovascular events.

Retatrutide may reduce triglycerides.

Triglycerides are a type of fat found in the blood. Raised triglycerides can occur alongside obesity, insulin resistance, fatty liver disease and type 2 diabetes.

Clinical trial data has shown reductions in triglycerides among people taking retatrutide. These changes may be partly linked to weight loss and broader improvements in metabolic health.

Retatrutide may help reduce systolic blood pressure in some people.

Systolic blood pressure is the top number in a blood pressure reading. High systolic blood pressure can increase the risk of heart disease, stroke and kidney problems.

Weight loss can help reduce blood pressure, but patients taking blood pressure medication should still be monitored by a healthcare professional. Retatrutide should not be seen as a replacement for prescribed blood pressure treatment.

Retatrutide may have potential benefits for people with metabolic dysfunction-associated steatotic liver disease, also known as MASLD.

MASLD happens when excess fat builds up in the liver and is commonly linked with obesity, insulin resistance and type 2 diabetes. In clinical research, retatrutide has been associated with reductions in liver fat.

This is promising, but retatrutide is not currently approved as a treatment for fatty liver disease. More research is needed to understand its long-term effect on liver inflammation, fibrosis and clinical liver outcomes.

Retatrutide may improve obstructive sleep apnoea severity in some people with obesity.

Obstructive sleep apnoea occurs when breathing repeatedly stops and starts during sleep. Excess weight can contribute by increasing pressure around the upper airway.

Clinical trial data suggests retatrutide may reduce sleep apnoea severity. This is likely linked at least partly to weight reduction, although the full relationship is still being studied.

Patients with sleep apnoea should not stop CPAP or other prescribed treatments unless advised by a clinician.

Retatrutide may reduce knee osteoarthritis pain in people with obesity.

Carrying excess weight places extra load through the knees. Reducing weight can lower joint stress and may improve pain, mobility and daily function.

Clinical trial data suggests retatrutide may reduce obesity-related knee osteoarthritis pain. However, it is not currently approved as an osteoarthritis treatment.

Retatrutide may improve some markers linked with inflammation and cardiometabolic risk.

Obesity is associated with chronic low-grade inflammation, which may contribute to metabolic and cardiovascular disease risk. Some trial data has reported improvements in inflammatory markers, although more research is needed before this can be linked to long-term disease reduction.

Retatrutide is being studied as a triple agonist, meaning it acts on three hormone receptor pathways involved in appetite, blood sugar and energy balance.

This may help explain why clinical trials have reported changes in several obesity-related health markers, not just body weight.

For a more detailed explanation of the science, read our guide on how retatrutide works.

Retatrutide has shown promising results in clinical trials, but it is not yet approved for routine use.

The benefits seen so far are based on research settings where participants are monitored closely. Real-world outcomes may differ if retatrutide is approved in the future.

It is also important to remember that clinical trial results do not mean retatrutide is suitable for everyone. Suitability would depend on medical history, current medicines, side effect risk and clinical assessment.

Further reading: Retatrutide results

Retatrutide is being studied mainly for weight loss, but its potential benefits may go beyond weight reduction.

Clinical trials suggest retatrutide may improve blood sugar control, waist circumference, triglycerides, non-HDL cholesterol, blood pressure, fatty liver, obstructive sleep apnoea severity and obesity-related knee pain.

These findings are promising, but retatrutide remains investigational. It is not currently approved in the UK and cannot legally be prescribed or bought as a licensed treatment.